# US 8,785,491 B2 · Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,491 B2
- Document ID: US8785491B2
- Status: Granted
- Kind: B2
- Application number: 13/063,672
- Filed: 2009-06-17
- Published: 2011-09-22
- Granted: 2014-07-22
- Earliest claimed: 2008-06-19
- Assignees: Takeda Pharmaceuticals U.S.A., Inc.
- Applicants: David Baron; Keisuke Hirai; Yasushi Shintani; Osamu Uchikawa
- Inventors: David Baron; Keisuke Hirai; Yasushi Shintani; Osamu Uchikawa
- Web page: https://patentgrep.com/patent/US8785491B2

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61P 27/02: Ophthalmic agents
- C07D 307/93: condensed with a ring other than six-membered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.

## Claims

### Claim 1

A method for treating age-related macular degeneration in a patient in need thereof, wherein said method comprises identifying a patient in need of treatment for age-related macular degeneration, and administering (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide to said patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is identified by visual examination of the patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein said age-related macular degeneration is the dry form.

### Claim 4 (depends on 1)

The method of claim 1, wherein said age-related macular degeneration is the wet form.

### Claim 5 (depends on 1)

The method of claim 1, wherein said age-related macular degeneration occurs in one eye.

### Claim 6 (depends on 1)

The method of claim 1, wherein said age-related macular degeneration occurs in two eyes.

### Claim 7 (depends on 1)

The method of claim 1, wherein said administration of (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by an oral dosage form.

### Claim 8 (depends on 1)

The method of claim 1, wherein said administration of (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by an injectable dosage form.

### Claim 9 (depends on 1)

The method of claim 1, wherein said administration of (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by a skin-patch dosage form.

### Claim 10 (depends on 1)

The method of claim 1, wherein said administration of (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide is by a liquid, powder, ointment, paste, gel or cream dosage form.

### Claim 11 (depends on 1)

The method of claim 1, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose of from 1 mg to 1000 mg.

### Claim 12 (depends on 1)

The method of claim 1, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno [5,4-b]furan-8-yl]ethyl]propionamide, is administered in a dose of from 1 mg to 1000 mg.

### Claim 13 (depends on 1)

The method of claim 1, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose once daily.

### Claim 14 (depends on 13)

The method of claim 13, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in the evening.

### Claim 15 (depends on 13)

The method of claim 13, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered prior to sleep.

### Claim 16 (depends on 1)

The method of claim 1, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose twice daily.

### Claim 17 (depends on 1)

The method of claim 1, wherein said (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide is administered in a dose more than twice daily.

### Claim 18 (depends on 1)

The method of claim 1, further comprising administering photodynamic therapy.

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering therapeutic amount of a pharmaceutical agent selected from the group consisting of bevacizumab, ranibizumab, melatonin, pegatanib, and combinations thereof.

### Claim 20

A method for treating age-related macular degeneration in a patient in need thereof, wherein said method comprises administering (S)—N-[2-[4-hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide to said patient.

### Claim 21 (depends on 20)

The method of claim 20, wherein said (S)N-[2-[4 hydroxy-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propionamide administered in a dose of from 1 mg to 1000 mg.

### Claim 22 (depends on 20)

The method of claim 20 further comprising administering photodynamic therapy.

### Claim 23 (depends on 20)

The method of claim 20, further comprising administering therapeutic amount of a pharmaceutical agent selected from the group consisting of bevacizumab, ranibizumab, melatonin, pegatanib, and combinations thereof.